Fireside chats feature candid discussions between biopharma CEOs and Wall Street analysts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2014.
To view the 2013 fireside chat speakers, click here.
Leonard Bell, M.D.
Chief Executive Officer
Alexion Pharmaceuticals, Inc.
Date and Location: TBA
Leonard Bell, M.D. is the Chief Executive Officer and principal founder of Alexion Pharmaceuticals. Under his continuous leadership since 1992, when he started the firm, Alexion has become a fast-growing and profitable global biopharmaceutical company, with more than 1,600 employees serving patients in 50 countries through fully integrated research, discovery, development, manufacturing and commercial capabilities.
Dr. Bell’s combination of scientific, clinical, regulatory and business skills have been central to Alexion’s accomplishments, from the early discovery and development of Soliris® (eculizumab) to the subsequent building and management of what is now a global commercial organization. Dr. Bell has emphasized strong growth and highly controlled use of financial resources as the Company continues its mission to develop life-transforming treatments for patients suffering with severe and life-threatening disorders that are also ultra-rare. Currently, under his leadership, Alexion’s commercial operations are driving the ongoing global launches of Soliris in PNH and aHUS, two life-threatening and ultra-rare disorders. At the same time, the company’s R&D organization is broadening and accelerating its development of new medical uses for Soliris, and is also developing additional highly innovative therapeutic candidates. In each of its ten current lead drug-development programs – which span medical specialties that include transplant, neurology, and metabolic disorders – the company is focused on providing a life-transforming, breakthrough treatment for patients with a severe and ultra-rare disease.
Prior to founding Alexion, Dr. Bell was an Attending Physician at Yale-New Haven Hospital and Assistant Professor of Medicine and Pathology at the Yale University School of Medicine, where he also received his M.D. degree. He remains on the faculty of the Yale University School of Medicine as an Adjunct Assistant Professor of Medicine and Pathology. Dr. Bell received his A.B. degree from Brown University.
CEO of the Consumer Health and Prescriptions Medicine Division, EMD Serono
Member of the Executive Board Merck KGaA, Germany, Darmstadt
Head of Pharmaceuticals Business
Date and Location: TBA
Stefan Oschmann, born on July 25, 1957 in Würzburg, Germany, has been a member of the Executive Board of Merck KGaA, Germany, Darmstadt since January 2011 and is responsible for Merck KGaA and Consumer Health divisions. Before joining Merck KGaA, Darmstadt, Germany, he worked for the Pharma company MSD (in the US and Canada Merck & Co.). There he served most recently as President of Emerging Markets. His prior positions at MSD included Member of Senior Management and Corporate Officer with responsibility for the business in Europe, the Middle East, Africa and Canada, Senior Vice President in charge of Worldwide Human Health Marketing, as well as Vice President of Europe and the German business. Before that, Stefan Oschmann held various positions in Belgium, the Netherlands, Austria and eastern Europe. Prior to joining MSD, Stefan Oschmann worked for the International Atomic Energy Agency IAEA from 1985 bis 1987 and for the German Animal Health Federation (BfT) from 1987 to 1989, a member association of the German Chemical Industry Association (VCI). Stefan Oschmann studied veterinary medicine at Ludwig-Maximilians-Universität in Munich from 1977 to 1982 and earned a doctorate there in 1985. He is married and has two children.
Richard F. Pops
Chairman & Chief Executive Officer
Date and Location: TBA
Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 1,200 employees and a portfolio of more than 20 commercial products. Mr. Pops currently serves on the Board of Directors of Neurocrine Biosciences, Acceleron Pharma, Epizyme, the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA).
David E.I. Pyott
Chairman of the Board & Chief Executive Officer
Date and Location: TBA
David E.I. Pyott joined Allergan on January 1, 1998. During his tenure, Mr. Pyott has transformed Allergan from a small eye care business to a global specialty pharmaceutical and medical device company with leadership positions in six medical specialties. Allergan is currently the fastest growing global ophthalmic company and holds leadership positions in other specialty areas including neurosciences, medical aesthetics and medical dermatology.
Mr. Pyott has driven the growth of Allergan by fueling internal development through significant investment in Research & Development while also identifying and leveraging unique, synergistic external opportunities. Allergan’s investment in Research & Development has increased from less than $100 million in 1998 to approximately $1 billion in 2013. Most notably, from an external perspective, in March 2006, Allergan acquired Inamed Corp. for over $3 billion to create the world’s largest medical aesthetics company. In 2007, Allergan acquired Groupe Laboratories Cornéal in France. Most recently, in December 2012, Allergan acquired SkinMedica, Inc. and is now the U.S. leader in the growing “physician dispensed” topical aesthetics category. In addition, in March 2013, Allergan acquired MAP Pharmaceuticals for almost $1 billion for its inhaled migraine therapy technology, cementing Allergan’s leadership in the U.S. migraine market.
Christopher A. Viehbacher
Chief Executive Officer, Sanofi
President of the EFPIA, European Federation of Pharmaceutical Industries and Associations
Christopher A. Viehbacher, holds German and Canadian nationalities. He is a graduate of the Queens University (Ontario - Canada) and a certified public accountant. Since December 2008, he has held the position of Chief Executive Officer, Sanofi and is a Board member, in addition to being a member of the Strategy Committee. He is also Chairman of Genzyme, which Sanofi acquired in February 2011.
Christopher started his career in finance at PriceWaterhouseCoopers and joined GlaxoSmithKline (GSK) in 1988. Throughout the next 20 years with the company, he acquired broad international experience in Europe, in the United States and in Canada. His last position, before joining Sanofi was President, Pharmaceutical Operations North America. He was also a member of the board and Co-Chairman of the Portfolio Management Board.
Christopher was elected President of the EFPIA (European Federation of Pharmaceutical Industries and Associations) in June 2013 for a period of 2 years.
Christopher was Chairman of PhRMA in the United States (December 2010 – April 2012) and since February 2011 is Chair of the CEO Roundtable on Cancer. This association brings together employers across the United States to develop and implement workplace initiatives that reduce the risk of cancer, enable early diagnosis, facilitate better access to best-available treatments and hasten the discovery of novel and more effective diagnostic tools and anti-cancer therapies. Over 120 organisations are now members, covering 3 million employees.
In 2003, the French government acknowledged his commitment to public health and business by awarding Christopher a knight of the French Legion of Honor. He received the prestigious 2012 Pasteur Foundation Award, recognizing his leadership role within the pharmaceutical industry’s support of research & development and improving health of the 7 billion people around the world. Amongst other commitments, Christopher is also a member of International Business Council (WEF) and a member of the Board of Visitors of Fuqua School of Business, Duke University.